Konstantinos Assimakopoulos

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Either Called “Chemobrain” or “Chemofog,” the Long-Term Chemotherapy-Induced Cognitive Decline in Cancer Survivors Is Real

Andreas A. Argyriou, Konstantinos Assimakopoulos, Gregoris Iconomou et al. · Journal of Pain and Symptom Management · 2010 · 209 citations · Full text

Neuro-oncology, Oncology, Cancer Therapeutics +12

Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy

Andreas A. Argyriou, Elisabeth Chroni, P. Polychronopoulos et al. · Neurology · 2006 · 101 citations

Pain Medicine, Oxaliplatin-induced Peripheral Neuropathy, Neuropathic Pain +16

Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer

Andreas A. Argyriou, Panagiotis Polychronopoulos, Gregoris Iconomou et al. · Acta Oncologica · 2007 · 86 citations · Full text

Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?

Andreas A. Argyriou, Panagiotis Polychronopoulos, Αngelos Koutras et al. · Supportive Care in Cancer · 2005 · 83 citations

Advanced Age, Aging, Geriatrics +9